# TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

> **NCT01336829** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 33 (actual)

## Conditions studied

- Hepatitis C
- HIV

## Interventions

- **DRUG:** ETR/telaprevir
- **DRUG:** TMC278/telaprevir
- **DRUG:** telaprevir/ETR
- **DRUG:** telaprevir/TMC278

## Key facts

- **NCT ID:** NCT01336829
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2012-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01336829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01336829, "TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01336829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*